Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2019 Oct 3;19(1):147–156. doi: 10.1158/1535-7163.MCT-18-1202

Figure 2. Increased survival with trebananib and a MET kinase inhibitor is associated with increased presence of the epithelial marker E-cadherin.

Figure 2.

(A) Western blot analysis of epithelial marker E-cadherin in tumor lysates derived from mice in the orthotopic study in each treatment group (n = 4–5 mice per group). Western blot densitometry analysis shows trend towards increase in the presence of E-cadherin in the combination group compared to other groups (n = 5 mice per group). (B) Representative images of tumors from each treatment group in the orthotopic study stained for vimentin expression with IHC. Optical densitometry analysis of all images (5 mice per group; 25–30 images per group) shows a significant decrease of vimentin expression in combination and single agent trebananib groups compared to vehicle control. Scale bar= 200 μm (C) Representative images of tumors from each treatment group in the orthotopic study stained for CA-9 expression with IHC. Optical densitometry analysis of all images (5 mice per group; 25–30 images per group) shows a significant decrease of CA-9 expression in combination group compared to vehicle control. Results are given as mean + SEM. *p-value = <0.05, **p-value = <0.005, ***p-value = <0.001, ****p-value = <0.0001.